Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study

Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke

(2021) Cathy S. Zhong et al.   STROKE

Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

(2020) Bruce C. V. Campbell et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Thrombolysis with alteplase 3–4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China

(2020) Huaguang Zheng et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis

(2020) Yi Dong et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke

(2019) Christopher Elnan Kvistad et al.   STROKE

Evidence that Tenecteplase Is Noninferior to Alteplase for Acute Ischemic Stroke

(2019) Adrian M. Burgos et al.   STROKE

National Institutes of Health Stroke Scale

(2019) Vicky Chalos et al.   STROKE

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

(2019) William J. Powers et al.   STROKE

Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke

(2018) Bruce C.V. Campbell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial

(2017) Nicola Logallo et al.   LANCET NEUROLOGY

Characteristics, management and response to alteplase in China versus non-China participants of the ENCHANTED trial

(2017) Lily Song et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Tenecteplase versus alteplase in stroke thrombolysis: An individual patient data meta-analysis of randomized controlled trials

(2016) Xuya Huang et al.   International Journal of Stroke

Low-Dose versus Standard-Dose Intravenous Alteplase in Acute Ischemic Stroke

(2016) Craig S. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke

(2015) Nicola Logallo et al.   CNS DRUGS

Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study

(2015) Xuya Huang et al.   LANCET NEUROLOGY

Low-Versus Standard-Dose Alteplase for Ischemic Strokes Within 4.5 Hours

(2015) Beom Joon Kim et al.   STROKE

Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials

(2014) Jonathan Emberson et al.   LANCET

Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Stroke Is Better Than Low Doses

(2014) Xiaoling Liao et al.   STROKE

A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke

(2012) Mark Parsons et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis

(2010) Charlotte JJ van Asch et al.   LANCET NEUROLOGY

Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke

(2010) E. Clarke Haley et al.   STROKE

Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke

(2008) Werner Hacke et al.   NEW ENGLAND JOURNAL OF MEDICINE